| Prev Close | 0.20 |
| Open | 0.22 |
| Day Low/High | 0.19 / 0.22 |
| 52 Wk Low/High | 0.13 / 1.08 |
| Volume | 627.31K |
| Exchange | NASDAQ |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Investors in Star Scientific, Inc. saw new options become available this week, for the April 19th expiration.
This biotech stock trading for under $10 is within range of triggering a breakout trade.
Investors in Star Scientific, Inc. saw new options become available this week, for the August 2014 expiration.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Investors considering a purchase of Star Scientific, Inc. stock, but cautious about paying the going market price of $1.40/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is notifying investors in Star Scientific, Inc.
A government investigation adds to Star Scientific's mounting problems.
Star Scientific still has questions to answer about anatabine.
Here is this week's roundup of the dumbest actions on Wall Street.
Gregg Greenberg skewers the biggest companies that made the best bloopers.
Levi & Korsinsky is investigating potential claims on behalf of purchasers of Star Scientific, Inc.
Johns Hopkins confirms it has no involvement with study of Star's nutritional supplement anatabine.
Levi & Korsinsky, LLP is investigating Star Scientific, Inc.
Adam Feuerstein, senior columnist for TheStreet, is assembling candidates for the Worst Biotech CEO of 2012 award.
Friday's financing transferred million of dollars from Star Scientific into the pockets of select shareholders.
Star Scientific's third-quarter report was both humiliating and humbling.
These stocks are among the most active in Friday's extended session.
Star changes results from an Anatabloc study without any explanation.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
Star's dietary supplement Anatabloc has minimal effect on CRP levels in study.
Star Scientific appears to have received little or nothing from RJR in the settled patent lawsuit.
Did Star Scientific win big money from R.J. Reynolds?
Forget Apple and Google. Banco Santander holds the key to this market, Cramer said.
Star Scientific says it will ask FDA to approve new tobacco-making method early next year
FedEx, Beazer Homes, Netflix, Wells Fargo, E-Trade are among big market movers Wednesday
RJ Reynolds wins tobacco curing patent fight with Star Scientific; Star shares plummet
Supreme Court refuses to get involved in tobacco patent fight
Shares were up 42.8% for no discernable reason.
